T umors are complex ecosystems defined by spatiotemporal interactions between heterogeneous cell types, including malignant, immune, and stromal cells (1) . Each tumor's cellular composition, as well as the interplay between these components, may exert critical roles in cancer development (2) . However, the specific components, their salient biological functions, and the means by which they collectively define tumor behavior remain incompletely characterized.
Tumor cellular diversity poses both challenges and opportunities for cancer therapy. This is exemplified by the varied clinical efficacy achieved in malignant melanoma with targeted therapies and immunotherapies. Immune checkpoint inhibitors can produce clinical responses in many patients with metastatic melanomas (3-7); however, the genomic and molecular determinants of response to these agents remain incompletely understood. Although tumor neoantigens and PD-L1 expression clearly correlate with this response (8) (9) (10) , it is likely that other factors from subsets of malignant cells, the microenvironment, and tumor-infiltrating lymphocytes (TILs) also play essential roles (11) .
Melanomas that harbor the BRAF V600E (V600E: Val 600 →Glu 600 ) mutation are commonly treated with inhibitors of rapidly accelerated fibrosarcoma kinase (RAF) and mitogen-activated protein kinase (MEK), before or after immune checkpoint inhibition. Although this regimen improves survival, virtually all tumors eventually develop resistance to these drugs (12, 13) . Unfortunately, no targeted therapy currently exists for patients whose tumors lack BRAF mutations-including NRAS mutant tumors, those with inactivating NF1 mutations, or rarer events (such as RAF fusions). Collectively, these factors highlight the need for a deeper understanding of melanoma composition and its effect on the clinical course.
The next wave of therapeutic advances in cancer will probably be accelerated by technologies that assess the malignant, microenvironmental, and immunologic states most likely to inform treatment response and resistance. Ideally, we would be able to assess salient cellular heterogeneity by quantifying variation in oncogenic signaling pathways; drug-resistant tumor cell subsets; and the spectrum of immune, stromal, and other cell states that may inform immunotherapy response. Toward this end, single-cell genomic approaches enable detailed evaluation of genetic and transcriptional features present in hundreds to thousands of individual cells per tumor (14) (15) (16) . In principle, this approach may allow us to identify all major cellular components simultaneously, determine their individual genomic and molecular states (15) , and ascertain which of these features may predict or explain clinical responses to anticancer agents. To explore this question, we used single-cell RNA sequencing (RNA-seq) to examine heterogeneities in malignant and nonmalignant cell types and states and to infer their possible drivers and interrelationships in the complex tumor cellular ecosystem.
Profiles of individual cells from patient-derived melanoma tumors
We measured single-cell RNA-seq profiles from 4645 malignant, immune, and stromal cells isolated from 19 freshly procured human melanoma tumors that span a range of clinical and therapeutic backgrounds (table S1). These included 10 metastases to lymphoid tissues (9 to lymph nodes and 1 to the spleen), 8 to distant sites (5 to subcutaneous or intramuscular tissue and 3 to the gastrointestinal tract), and one primary acral melanoma. Genotypic information was available for 17 of the 19 tumors, of which 4 had activating mutations in BRAF and 5 in NRAS oncogenes; eight patients had BRAF/NRAS wild-type melanomas (table S1) .
To isolate viable single cells that are suitable for high-quality single-cell RNA-seq, we developed and implemented a rapid translational workflow (Fig. 1A) (15) . We processed tumor tissues immediately after surgical procurement and generated single-cell suspensions within~45 min, using an experimental protocol optimized to reduce artifactual transcriptional changes introduced by disaggregation, temperature, or time (17) . Once in suspension, we recovered individual viable immune (CD45 + ) and nonimmune (CD45 -) cells (including malignant and stromal cells) by flow cytometry (fluorescence-activated cell sorting). Next, we prepared cDNA from the individual cells, followed by library construction and massively parallel sequencing. The average number of mapped reads per cell was~150,000 (17) , with a median library complexity of 4659 genes for malignant cells and 3438 genes for immune cells, comparable to previous studies of only malignant cells from fresh glioblastoma tumors (15) .
Single-cell transcriptome profiles distinguish cell states in malignant and nonmalignant cells
We used a multistep approach to distinguish the different cell types within melanoma tumors on the basis of both genetic and transcriptional states (Fig. 1, B to D) . First, we inferred largescale copy number variations (CNVs) from expression profiles by averaging expression over stretches of 100 genes on their respective chromosomes (15) (Fig. 1B) . For each tumor, this approach revealed a common pattern of aneuploidy, which we validated in two tumors by bulk whole-exome sequencing (WES) (Fig. 1B and fig.  S1A ). Cells in which aneuploidy was inferred were classified as malignant cells (Fig. 1B and  fig. S1 ).
Second, we grouped the cells according to their expression profiles (Fig. 1, C and D, and  fig. S2 ). To do this, we used nonlinear dimensionality reduction [t-distributed stochastic neighbor embedding (t-SNE)] (18), followed by density clustering (19) . Generally, cells designated as malignant by CNV analysis formed a separate cluster for each tumor (Fig. 1C) , suggesting a high degree of intertumor heterogeneity. In contrast, the nonmalignant cells clustered by cell type (Fig. 1D and fig. S2 ), independent of their tumor of origin and metastatic site ( fig.  S3 ). Clusters of nonmalignant cells were annotated as T cells, B cells, macrophages, endothelial cells, cancer-associated fibroblasts (CAFs), and natural killer cells on the basis of their preferentially or distinctively expressed marker genes (Fig.  1D, fig. S2 , and tables S2 and S3). Fig. 2A and fig. S4A ). These signatures revealed variability in the fraction of cycling cells across tumors (13.5% on average, ±13 SD) ( fig. S4B ), allowing us to designate both low-cycling (1 to 3%, e.g., Mel79) and high-cycling tumors (20 to 30%, e.g., Mel78), consistent with Ki67 + staining results ( Fig. 2B and fig. S4C ).
Analysis
A core set of cell cycle genes was induced (fig .  S4D , red dots; and table S5) in both low-cycling and high-cycling tumors, with one notable exception: cyclin D3 (CCND3), which was induced in cycling cells only in high-cycling tumors ( fig.  S4D ). In contrast, KDM5B (JARID1B) showed the strongest association with noncycling cells (Fig. 2A, green dots) , mirroring Patel et al.'s findings in glioblastoma (15) . KDM5B encodes a H3K4 histone demethylase associated with a subpopulation of slow-cycling and drug-resistant melanoma stemlike cells (21, 22) in mouse models. Immunofluorescence (IF) staining validated the presence and mutually exclusive expression of KDM5B and Ki67. KDM5B-expressing cells were grouped in small clusters, consistent with observations in mouse and in vitro models (21) (Fig. 2C and fig. S4E ).
Two principal components (PC3 and PC6) primarily segregated different malignant cells from one treatment-naïve tumor (Mel79). In this tumor, we analyzed 468 malignant cells from four distinct S6 and  table S6) , suggesting a spatial effect that influences multiple cell types. The genes with the highest preferential expression in region one are also generally coexpressed across melanoma tumors profiled in bulk in The Cancer Genome Atlas (TCGA) (23) (fig. S6 ). Many of these genes encode immediate early-activation transcription factors linked to inflammation, stress responses, and a melanoma oncogenic program (e.g., ATF3, FOS, FOSB, JUN, JUNB). Several of these transcription factors (e.g., FOS, JUN, NR4A1/2) are regulated by cyclic adenosine monophosphate (cAMP) and cAMP response element-binding protein signaling, which has been implicated as a mitogen-activated protein kinase (MAPK)-independent resistance module in BRAF-mutant melanomas treated with RAF and MEK inhibition (24) . Other top genes differentially up-regulated in region one included those involved in survival (MCL1), stress responses (EGR1/2/ 3, NDRG, HSPA1B), and NF-kB signaling (NFKBIZ), which has also been associated with resistance to RAF and MEK inhibition (25) . Ranked melanoma 79 cancer cells
Mel78-Ki67 subsets of malignant cells that are less likely to respond to targeted therapy. The transcriptional programs associated with principal components PC4 and PC5 were highly correlated with expression of the MITF gene (microphthalmiaassociated transcription factor), which encodes the master melanocyte transcriptional regulator and a melanoma lineage-survival oncogene (26) . Scoring genes by their correlation to MITF across single cells, we identified a "MITF-high" program consisting of MITF itself and several MITF target genes, including TYR, PMEL, and MLANA (table S7) . A second transcriptional program, negatively correlated with the MITF program and with PC4 and PC5 (Pearson correlation P < 10
), included AXL and NGFR (p75NTR), a marker of resistance to various targeted therapies (27, 28) and a putative melanoma cancer stem cell marker (29) , respectively (table  S8) . Thus, these transcriptional programs resemble reported (25, (30) (31) (32) MITF-high, as well as MITF-low and AXL-high ("AXL-high"), transcriptional profiles that can distinguish melanoma tumors, cell lines, and mouse models. Notably, the AXL-high program has been linked to intrinsic resistance to RAF and MEK inhibition (25, 30, 31) . Although at the bulk tumor level each melanoma could be classified as MITF-high or AXLhigh (Fig. 3A) , at the single-cell level every tumor contained malignant cells corresponding to both transcriptional states. Using single-cell RNA-seq to examine each cell's expression of the MITF and AXL gene sets, we observed that MITF-high tumors, including treatment-naïve melanomas, harbored a subpopulation of AXL-high melanoma cells that was undetectable through bulk analysis, and vice versa (Fig. 3B) . The malignant cells thus spanned the continuum between AXLhigh and MITF-high states in every investigated tumor (Fig. 3B and fig. S7 ). We performed IF staining to further validate the mutually exclusive expression of the MITF-high and AXL-high programs in cells from the same bulk tumors (Fig. 3C and fig. S8 ).
Because malignant cells with AXL-high and MITF-high transcriptional states coexist in melanoma, we hypothesized that treatment with RAF and MEK inhibitors would increase the prevalence of AXL-high cells after the development of drug resistance. To test this, we analyzed RNA-seq data from a cohort (13) of six paired BRAF V600E melanoma biopsies taken before treatment and after resistance to single-agent RAF inhibition (vemurafenib; 1 patient) or combined RAF and MEK inhibition (dabrafenib and trametinib; 5 patients), respectively (tables S9 and S10). We ranked the 12 transcriptomes on the basis of the relative expression of all genes in the AXLhigh program compared with those in the Fig. 3D ; P < 0.05 for same effect in six of six paired samples, binomial test; P < 0.05 for four of six individual pairedsample comparisons shown by black arrows (17)]. RNA-seq data from an independent cohort (33) also showed that a subset of drug-resistant samples exhibited increased expression of the AXL program ( fig. S9 ). Other genes previously implicated in resistance to RAF and MEK inhibition were also increased in a subset of the drug-resistant samples. PDGFRB (platelet-derived growth factor receptor b) (34) was up-regulated in a similar subset as the AXL program, whereas MET (33) was up-regulated in a mutually exclusive subset ( fig. S9 ), suggesting that AXL and MET may reflect distinct drug-resistant states.
To (table S11) . Flow cytometry analysis revealed a wide distribution of the proportion of AXL-positive cells, from <1 to 99% per cell line, which correlated with bulk mRNA levels and was inversely associated with sensitivity to small-molecule RAF inhibition (table S11) .
We treated 10 cell lines (17) (dabrafenib and trametinib) and found an increase in the proportion of AXL-positive cells in 6 cell lines initially composed of a small (<3%) pretreatment AXL-positive population ( fig. S10A) . In contrast, cell lines with an intrinsically high proportion of AXL expression showed modest or no changes ( fig. S10B) . We obtained similar results by multiplexed quantitative single-cell IF, which also demonstrated that the increased fraction of AXL-positive cells after inhibition of RAF and MEK is associated with rapid decreases in extracellular signal-regulated kinase (ERK) phosphorylation (reflecting MAP kinase signaling inhibition) (Fig. 3E and figs. S11 and S12). In summary, both melanoma tumors and cell Tregs   NKG7  CCL4  CST7  PRF1  GZMA  GZMB  IFNG  CCL3   CXCL13  TNFRSF1B  RGS2  TIGIT  CD27  TNFRSF9  SLA  RNF19A  INPP5F  XCL2  HLA-DMA  FAM3C  UQCRC1  WARS  EIF3L  KCNK5  TMBIM6  CD200  ZC3H7A  SH2D1A  ATP1B3  MYO7A  THADA  PARK7  EGR2  FDFT1  CRTAM  IFI16   PD1  TIGIT  LAG3  TIM3  CTLA4  CCR7  TCF7 , binomial test).
lines demonstrate drug-resistant tumor cell subpopulations that precede treatment and become enriched after MAP kinase-targeted treatment.
Nonmalignant cells and their interactions within the melanoma microenvironment
Various nonmalignant cells make up the tumor microenvironment. The composition of the microenvironment has an important effect on tumorigenesis and also in the modulation of treatment responses (1) . Tumor infiltration with T cells, for example, is predictive for the response to immune checkpoint inhibitors in various cancer types (36) .
To resolve the composition of the melanoma microenvironment, we used our single-cell RNAseq profiles to define distinct expression signatures of each of five distinct nonmalignant cell types: T cells, B cells, macrophages, endothelial cells, and CAFs. Because our signatures were derived from single-cell profiles, we could avoid confounders and ensure that each signature is determined by cell type-specific profiles (17) . Next, we used these signatures to infer the relative abundance of those cell types in a larger compendium of tumors (17) (Fig. 4A and fig. S13 ). We found a strong correlation (correlation coefficient R~0.8) between our estimated tumor purity and that predicted from DNA analysis (37) (Fig. 4A , first lane below the heat map).
We partitioned 471 tumors from TCGA into 10 distinct microenvironment clusters on the basis of their inferred cell type composition (Fig.  4A ). Clusters were mostly independent of the site of metastasis (Fig. 4A, second lane) , with some exceptions (e.g., clusters 8 and 9). Next we examined how these different microenvironments may relate to the phenotype of the malignant cells. In particular, CAF abundance is predictive of the AXL-MITF distinction, with CAF-rich tumors expressing the AXL-high signature (Fig. 4A,  bottom lane) . Interestingly, an AXL-high program was expressed by both melanoma cells and CAFs. However, we distinguished AXL-high genes that are preferentially expressed by melanoma cells ("melanoma-derived AXL program") from those that are preferentially expressed by CAFs ("CAFderived AXL program"). Both sets of genes were correlated with the inferred CAF abundance in tumors from TCGA ( fig. S14) (38) . Furthermore, the MITF-high program, which is specific to melanoma cells, was negatively correlated with inferred CAF abundance. Taken together, these results suggest that CAF abundance may be linked to preferential expression of the AXL-high over the MITF-high program by melanoma cells. Thus it is possible that specific tumor-CAF interactions may shape the melanoma cell transcriptome.
Interactions between cells play crucial roles in the tumor microenvironment (1) . To assess how cell-to-cell interactions may influence tumor composition, we searched for genes expressed by cells of one type that may influence or reflect the proportion of cells of a different type in the tumor ( fig. S15 ). For example, we searched for genes expressed primarily by CAFs (but not T cells) in single-cell data that correlated with T cell abundance (as inferred by T cell-specific genes) in bulk tumor tissue from the TCGA data set (23) . We identified a set of CAF-expressed genes that correlated strongly with T cell infiltration (Fig. 4B , red circles). These included known chemotactic (CXCL12 and CCL19) and immune-modulating (PD-L2) genes, which are expressed by both CAFs and macrophages ( fig. S16) . A separate set of genes, exclusively expressed by CAFs, that correlated with T cell infiltration ( fig. S16 ) included multiple complement factors [C1S, C1R, C3, C4A, CFB, and C1NH (SERPING1)]. Notably, these complement genes were specifically expressed by freshly isolated CAFs but not by cultured CAFs (fig.  S17) or macrophages (fig. S16 ). These findings are intriguing, as studies have implicated complement activity in the recruitment and modulation of T cell-mediated antitumor immune responses [in addition to their role in augmenting innate immunity (39) ].
We validated a high correlation (R > 0.8) between complement factor 3 (C3) levels (one of the CAF-expressed complement genes) and infiltration of CD8 + T cells. We performed dual IF staining and quantitative slide analysis of two tissue microarrays with a total of 308 core biopsies, including primary tumors, metastatic lesions, normal skin with adjacent tumor, and healthy skin controls (Fig. 4C and fig. S18 ) (17) . To test the generalizability of the association between CAF-derived complement factors with T cell infiltration, we expanded our analysis to bulk RNAseq data sets across all TCGA cancer types (Fig.  4D) . Consistent with the results in melanoma, complement factors correlated with inferred T cell abundance in many cancer types and more highly than in normal tissues (e.g., R > 0.4 for 65% of cancer types but only for 14% of normal tissue types). Although correlation analysis cannot determine causality, this indicates a potential in vivo role for cell-to-cell interactions.
Diversity of tumor-infiltrating T lymphocytes and their functional states
The activity of TILs, particularly CD8 + T cells, is a major determinant of successful immune surveillance. Under normal circumstances, effector CD8 + T cells exposed to antigens and costimulatory factors may mediate lysis of malignant cells and control tumor growth. However, this function can be hampered by tumor-mediated T cell exhaustion, such that T cells fail to activate cytotoxic effector functions (40) . Exhaustion is promoted through the stimulation of coinhibitory checkpoint molecules on the T cell surface (PD-1, TIM-3, CTLA-4, TIGIT, LAG3, and others) (41); blockade of checkpoint mechanisms has shown clinical benefit in subsets of melanoma and other malignancies (3, 10, 42, 43) . Although checkpoint ligand expression (e.g., PD-L1) and neoantigen load clearly contribute (9, 44, 45) , no biomarker has emerged that reliably predicts the clinical response to immune checkpoint blockade. We reasoned that single-cell analyses might yield features to elucidate response determinants and possibly identify new immunotherapy targets. (Fig. 5A , top, and table S12). Within both the CD4 + and CD8 + populations, a PCA distinguished cell subsets and heterogeneity of activation states on the basis of the expression of naïve and cytotoxic T cell genes (Fig. 5, A  and B, and fig. S19 ).
Next we sought to determine the exhaustion status of each cell from the expression of key coinhibitory receptors (PD1, TIGIT, TIM3, LAG3, and CTLA4). In several cases, these coinhibitory receptors were coexpressed across individual cells; we validated this phenomenon for PD1 and TIM3 by IF staining (Fig. 5C ). However, exhaustion gene expression was also highly correlated with the expression of both cytotoxicity markers and overall T cell activation states (Fig. 5B) . This observation resembles an activation-dependent exhaustion expression program, such as those reported previously (46, 47) . Accordingly, expression of coinhibitory receptors (alone or in combinations) may not be sufficient by itself to characterize the salient functional state of tumor-associated T lymphocytes in situ or to distinguish exhaustion from activation.
To define an activation-independent exhaustion program, we leveraged single-cell data from CD8 + T cells sequenced in a single tumor (Mel75, 314 cells). These data allowed cytotoxic and exhaustion programs to be deconvolved. Specifically, PCA of Mel75 T cell transcriptomes identified a robust expression module that consisted of all five coinhibitory receptors and other exhaustion-related genes, but not cytotoxicity genes ( fig. S21 and table S13) .
We used the Mel75 exhaustion program, along with previously published exhaustion programs (46, 48) , to estimate the exhaustion state of each cell. An exhaustion state was defined as high or low expression of the exhaustion program relative to that of the cytotoxicity genes (Fig. 5D) (17) . Accordingly, we defined exhaustion states in Mel75 and in four additional tumors with the highest number of CD8 + T cells (68 to 214 cells per tumor). We identified the top preferentially expressed genes in high-exhaustion cells compared with low-exhaustion cells (both defined relative to the expression of cytotoxicity genes). This allowed us to define a core exhaustion signature across cells from various tumors.
Our core exhaustion signature yielded 28 genes that were consistently up-regulated in high-exhaustion cells of most tumors, including coinhibitory (TIGIT) and costimulatory (TNFRSF9/ 4-1BB and CD27) receptors (Fig. 5E and table S14 ). In addition, most genes that were significantly up-regulated in high-exhaustion cells of at least one tumor had distinct associations with exhaustion across the different tumors (Fig. 5F , 272 of 300 genes with P < 0.001 by permutation test; fig. S22 , A and B; and table S14). These tumorspecific signatures included variable expression of known exhaustion markers (table S14) and could be linked to immunotherapeutic response or might reflect the effects of previous treatments. For example, CTLA-4 was highly up-regulated in exhausted cells of Mel75 and weakly up-regulated in three other tumors but was completely decoupled from exhaustion in Mel58. Interestingly, Mel58 was derived from a patient with an initial response and subsequent development of resistance to CTLA-4 blockade with ipilimumab ( Fig. 5F and fig. S22C ). Another variable gene of interest was the transcription factor NFATC1, previously implicated in T cell exhaustion (49) . NFATC1 and its target genes were preferentially associated with the activation-independent exhaustion phenotype in Mel75 (fig. S22, D and  E) , suggesting a potential role of NFATC1 in the underlying variability of exhaustion programs among patients.
Finally, we explored the relationship between T cell states and clonal expansion. T cells that recognize tumor antigens may proliferate to generate discernible clonal subpopulations defined by an identical T cell receptor (TCR) sequence (50) . To identify potentially expanded T cell clones, we used RNA-seq reads that map to the TCR to classify single T cells by their isoforms of the V and J segments of the a and b TCR chains, and we searched for enriched combinations of TCR segments. Most observed combinations were found in few cells and were not enriched. However, approximately half of the CD8 + T cells in Mel75 had one of the seven enriched combinations identified (FDR = 0.005) and thus may represent expanded T cell clones (Fig.  5G and fig. S23 ). This putative T cell expansion was also linked to exhaustion (Fig. 5H) , such that low-exhaustion T cells were depleted in expanded T cells (TCR clusters with more than six cells) and enriched in nonexpanded T cells (TCR clusters with one to four cells). In particular, the nonexhausted cytotoxic cells are almost all nonexpanded cells (Fig. 5H) . Overall, this analysis suggests that single-cell RNA-seq may allow for the inference of functionally variable T cell populations that are not detectable with other profiling approaches ( fig. S24 ). This knowledge may empower studies of tumor response and resistance to immune checkpoint inhibitors.
Conclusions
Our analysis has uncovered intra-and interindividual, spatial, functional, and genomic heterogeneity in melanoma cells and associated tumor components that shape the microenvironment, including immune cells, CAFs, and endothelial cells. We identified a cell state in a subpopulation of all melanomas studied that is linked to resistance to targeted therapies, and we used a variety of approaches to validate the presence of a dormant drug-resistant population in a number of melanoma cell lines.
By leveraging single-cell profiles from a few tumors to deconvolve a large collection of bulk profiles from TCGA, we discovered different microenvironments associated with distinct malignant cell profiles. We also detected a subset of genes expressed by one cell type (e.g., CAFs) that may influence the proportion of other cell types (e.g., T cells); this indicates the importance of intercellular communication for tumor phenotype. Putative interactions between stromal-derived factors and immune cell abundance in melanoma core biopsies suggest that future diagnostic and therapeutic strategies should account for tumor cell composition rather than bulk expression. Furthermore, our data suggest potential biomarkers for distinguishing exhausted and cytotoxic T cells that may aid in selecting patients for immune checkpoint blockade.
Although future work is necessary to clarify the interplay between these cell types and functional states in space and time, the ability to carry out a number of highly multiplexed singlecell observations within a tumor allows us to identify meaningful cell subpopulations and gene expression programs that may inform both the analysis of bulk transcriptional data and precision treatment strategies. Conceivably, single-cell genomic profiling may soon enable a deeper understanding of the complex interplay among cells within the tumor ecosystem and its evolution in response to treatment, thereby providing a versatile new tool for future translational applications.
